Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
Nyxoah, a medical technology company specializing in Obstructive Sleep Apnea (OSA) solutions, announced a reduction in the maximum shares available under its at-the-market equity offering program. The original cap of 6,000,000 ordinary shares has been decreased by 1,569,139 shares, bringing the new total to 4,430,861 shares. Consequently, 3,662,699 shares remain available for issuance. This adjustment increases the authorized capital by EUR 269,579. The announcement does not constitute a sale offer or solicitation. For more details, refer to section 1.5.2 of the May 22, 2024 board report on Nyxoah's investor page.
- Reduction in shares available under the offering program may prevent share dilution.
- Authorized capital increase by EUR 269,579 gives the board more financial flexibility.
- Reduction in available shares could limit the company's ability to raise capital quickly.
- Potential investor concerns about future fundraising capability and financial stability.
Insights
Nyxoah, a company specializing in medical technology, has announced a reduction in its at-the-market (ATM) equity offering program. This move involves a decrease of
From a financial perspective, this decision may indicate that Nyxoah is adjusting its capital-raising strategy, possibly due to current market conditions or internal funding needs. Reducing the number of shares available for issuance can help prevent dilution of existing shares, which is generally favorable for current shareholders as it maintains their ownership percentage and the value of their shares.
In the short term, this move could stabilize or potentially increase Nyxoah's stock price by signaling to investors that the company is confident in its financial position and doesn't foresee a need for aggressive capital raising. However, if the company needs additional funds in the future but cannot raise them as easily, this could limit its flexibility.
In the long term, the impact of this reduction will depend on Nyxoah's financial performance and its ability to meet funding needs through other means. Investors should monitor Nyxoah's financial health and any further communications from the company regarding its funding strategy.
Nyxoah's strategic adjustment in its at-the-market offering program presents a mixed signal to the market. On one hand, reducing the share issuance can indicate confidence in the company's cash flow and funding alternatives, which might reassure investors about Nyxoah's operational stability. This is particularly important in the medical technology sector, where companies often require significant capital for R&D and regulatory approval processes.
On the other hand, the reduction might be interpreted as a cautious approach to the market, possibly due to current investor sentiment or market volatility. Investors should consider this context and watch for subsequent financial reports or strategic announcements that could provide more clarity on Nyxoah's financial planning and market positioning.
For retail investors, it’s important to look beyond this announcement and consider the overall market conditions and Nyxoah's pipeline of products, especially those in advanced stages of development or nearing commercialization. Comparing Nyxoah's strategy with industry peers can also provide insights into the company's relative market position.
REGULATED INFORMATION
INSIDE INFORMATION
Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program
Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its “at-the-market” offering (announced on December 22, 2022) by an amount of 1,569,139 ordinary shares, or share capital of EUR 269,579 (excluding issuance premium), resulting in (i) a maximum of 4,430,861 ordinary shares to be issued under its “at-the-market” offering, of which 3,662,699 ordinary shares remain available for issuance, and (ii) an increase of the authorized capital that is available to the board of directors by EUR 269,579. For further context, please refer to section 1.5.2 of the May 22, 2024 board report that is available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials > Special Reports).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading "Risk Factors" in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
Attachment
FAQ
What did Nyxoah announce on May 22, 2024?
How many shares are now available for issuance under Nyxoah's equity offering program?
What is the new maximum amount of shares available under Nyxoah's offering program?
How much did Nyxoah's authorized capital increase due to the share reduction?
What is the significance of the reduction in Nyxoah's equity offering program?
